Dr. David Goodrich, Professor of Oncology at Roswell Park Cancer Institute, is co-author of a study offering new insights on preventing androgen-deprivation therapy resistance for prostate cancer. The research also examines the Rb1 and Ezh2 genes and their role in the occurrence of metastatic prostate cancer.
Improving Androgen-Deprivation Therapy for Prostate Cancer
